New York, June 4, 2026, 04:16 (EDT)
bioAffinity Technologies Inc. (Nasdaq) traded at $1.69 in the latest quote, up five cents from its last close. The stock caught a small bump after the diagnostics firm filed a new notice on physician education related to its CyPath Lung cancer test. With a market cap near $7.6 million, any buying or selling tends to swing the share price.
Society for Advanced Bronchoscopy is planning a June 16 webinar to talk about CyPath Lung and its use in pulmonary, oncology, and surgical work for early lung cancer detection and management, according to a June 2 filing. Shares and warrants of the company are listed on Nasdaq Capital Market under the symbols BIAF and BIAFW.
Why now: bioAffinity is seeing faster CyPath Lung uptake, but the company still needs that pickup to become lasting revenue before its cash situation takes focus again. In its first-quarter update in May, bioAffinity said CyPath Lung units sold jumped 146% over last year. CyPath Lung testing revenue was up about 114% to $361,000, while overall consolidated revenue dropped to $1.4 million from $1.9 million because the company left some money-losing pathology business. CEO Maria Zannes said bioAffinity aims to “bridge the diagnostic gap between imaging and invasive procedures.” Nasdaq
CyPath Lung is a lab-developed test, or LDT, built and run inside one lab. The FDA’s 2024 rule to expand LDT oversight was thrown out by a federal court in 2025. CMS says CLIA rules target accuracy, reliability, and timeliness in lab test results.
The latest webinar invite gives the company another place to promote the test to doctors treating indeterminate lung nodules — spots on scans that could be cancer. Gordon Downie, chief medical officer at bioAffinity, said there’s a “significant increase” in these patients and called CyPath Lung a complement to bronchoscopy for smaller nodules. Zannes said the SAB event was a chance to talk about new tools like CyPath Lung.
CT scans can spot lung nodules, but the scans alone can’t tell if a nodule is cancer. That means doctors have to weigh more scans against a biopsy or surgery, which can be costly and risky if the nodule turns out to be harmless.
bioAffinity said in May that preliminary, unaudited numbers show April CyPath Lung unit sales hit a one-month high, up almost 300% from April 2025. Zannes said at the time that “growth in CyPath Lung usage continues to accelerate.” The company also said the test should not be used alone and needs to be considered with other clinical info. bioAffinity Technologies, Inc.
The company has competition in the lung-nodule arena. Biodesix has its Nodify Lung blood-based tests aimed at risk assessment, and Veracyte offers Percepta Nasal Swab, which it calls a non-invasive molecular diagnostic for assessing nodules in patients with a smoking background.
Stocks lost ground on Wednesday. The Nasdaq dropped 0.89% and the S&P 500 slipped 0.74%. Reuters said investors stepped back from records with worries around Middle East tensions and rising oil.
Not a holiday or weekend summary. Nasdaq’s schedule puts Juneteenth on June 19 as the next full market closure, and it sets pre-market trading from 4:00 a.m. to 9:30 a.m. Eastern on business days.
But risk is clear. bioAffinity reported $1.7 million in cash and equivalents at May 4 in its latest quarterly filing, saying that cash could last through June 2026. Still, the company flagged “substantial doubt” about staying in business for the next 12 months if it can’t get more revenue or new funding. It warned that not raising capital could mean cutting operations, delaying trials, shutting down, or bankruptcy. bioAffinity Technologies, Inc.
BIAF is looking to the June 16 physician event and some recent sales announcements to trigger new orders, attract payers, or pull in investor backing. If that doesn’t happen, the company stays in micro-cap territory. It’s still a diagnostics play with a product pitch and little room on the balance sheet.
